Toru Yoshimitsu
Direktor/Vorstandsmitglied bei OCATA THERAPEUTICS INC
Aktive Positionen von Toru Yoshimitsu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| OCATA THERAPEUTICS INC | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Toru Yoshimitsu
Ehemalige bekannte Positionen von Toru Yoshimitsu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Astellas Pharma Europe Ltd.
 Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Direktor/Vorstandsmitglied | 01.04.2017 | 31.03.2020 |
| AUDENTES THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 15.01.2020 | - |
Statistik
International
| Vereinigte Staaten | 3 |
| Vereinigtes Königreich | 2 |
Operativ
| Director/Board Member | 3 |
Sektoral
| Health Technology | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
- Börse
- Insiders
- Toru Yoshimitsu
- Erfahrung
